Company Updates

News & Insights

Stay informed on the latest developments, industry trends, and company announcements from RxAir360 Inc.

Research Brief — Part 1 • April 10, 2026

The Hyperbaric Access Gap — DMV Region

First in a 4-part series — A data-driven analysis of geographic disparities in hyperbaric oxygen therapy access across the DC, Maryland, and Virginia region.

The 2-page Executive Teaser provides a concise synopsis of the full research brief, summarizing key findings for investors and stakeholders seeking a quick overview.

Woman analyzing digital map and network connections on tablet with city skyline in background

Research Highlights

  • Quantified physician practice density vs. HBOT facility availability
  • Geographic mapping of underserved communities in the DMV region
  • Infrastructure expansion opportunity analysis

Download the Research Brief

Executive Teaser (2-Page Synopsis) Full Research Brief

Parts 2, 3 & 4 coming soon — This is the first installment in a 4-part research series

Founder's Letter • March 13, 2026

Why Hyperbaric Medicine Is Entering Its Infrastructure Phase

Hyperbaric oxygen therapy (HBOT) is an FDA-cleared treatment for 14 approved conditions—yet the United States has fewer than 1,400 treatment facilities.

By comparison, dialysis expanded to 7,500+ centers, imaging expanded to 6,900+ facilities, and urgent care to 10,000 clinics nationwide.

The therapy works. Infrastructure hasn't.

Professional female surgeon reviewing patient data on monitor

Why This Matters

  • Reveals the infrastructure gap that has quietly limited access to HBOT
  • Explains why access to hyperbaric care remains a growing concern for veterans suffering from traumatic brain injury and related conditions
  • Discover the catalyst that could accelerate HBOT adoption the way dialysis expanded in the 1990s

"The science behind HBOT is well established. Access is not. Hyperbaric medicine is not limited by science — it is limited by infrastructure."

— Diallo M. Watts, Sr., Founder & CEO, RxAir360 Inc.

Inside the Founder's Letter

The Founder's Letter explains three forces driving this infrastructure shift—and why now is the tipping point

Read the Full Founder's Letter
November 2025 • Market Analysis

HBOT Market Poised for Strong Growth: Monoplace Chambers Lead the Way

Recent market data show that the global hyperbaric oxygen therapy (HBOT) market is entering a high-growth phase — expanding from roughly US $3.98 billion in 2025 to more than US $6.7 billion by 2034 (Precedence Research).

Monoplace chambers — compact systems designed for a single patient — are driving the largest share of this expansion as hospitals and physician offices increasingly adopt outpatient-friendly HBOT solutions (Future Market Insights).

Businesswomen pointing to arrow up virtual to forecast and analyze the stock market and economic year 2025 with virtual chart, trend upside business market growth, investments and financial concept.

Why This Matters for RxAir360

  • Strengthens the business case for RxAir360's vertical monoplace chamber, purpose-built for office integration
  • Highlights growing demand and reimbursement potential across multiple specialties
  • Supports the investor narrative of a large and expanding total addressable market

"The HBOT industry is growing quickly. Upon receiving FDA 510(k) clearance, RxAir360 intends to be positioned to offer a safer, smarter, and more accessible chamber design for physicians seeking to integrate HBOT into their practices."

— Diallo M. Watts Sr., Founder & CEO of RxAir360 Inc.

Key Takeaway: With the HBOT market set to nearly double in size this decade, RxAir360's physician-office chamber is at the forefront of next-generation oxygen therapy.

November 2025 • Safety & Compliance

Safety and Compliance Take Center Stage in the HBOT Industry

A series of incidents this year — including a tragic chamber fire in Michigan that led to criminal charges and another fatal flash fire in Arizona (People.com, Washington Post) — have brought renewed scrutiny to hyperbaric oxygen therapy (HBOT) safety and facility compliance nationwide.

These events have prompted regulators and manufacturers alike to emphasize stricter adherence to NFPA and ASME standards, fire-suppression systems, and operational safety training.

At RxAir360, Safety Isn't an Afterthought — It's Engineered Into Every Detail

The company's vertically oriented monoplace chamber incorporates redundant pressure sensors, precision-calibrated valves, and automated venting to ensure a controlled decompression sequence under all conditions.

Intelligent Technician-Response Safeguard

If the operator remains idle for more than ten minutes during treatment, the system automatically prompts them to confirm activity at the control panel.

If no response is detected, the chamber initiates a safe, automatic decompression cycle, allowing the patient to exit independently and ensuring protection in the event of a technician emergency or loss of responsiveness.

Redundant Pressure Sensors

Multiple monitoring systems

Precision-Calibrated Valves

Automated safety controls

Automated Venting

Controlled decompression

"Safety has always been our north star. From redundant pressure sensors to automated technician safeguards, our chamber is designed to think ahead — protecting both patient and provider."

— Diallo M. Watts Sr., Founder & CEO of RxAir360 Inc.

This forward-thinking approach positions RxAir360 as a leader in clinical-grade safety innovation, aligning its design philosophy with the highest standards of patient care and risk mitigation.

Key Takeaway: As the HBOT industry faces heightened safety scrutiny, RxAir360 continues to prioritize engineering precision, intelligent automation, and physician confidence.

February 2026 • Company Milestone

RxAir360 Completes Form 211 Filing, Positions for OTC Market Quotation

RxAir360 Inc. has completed its Form 211 filing with market maker Glendale Securities and transfer agent Dynamic Stock Transfer in preparation for quotation on the OTC Markets. This filing represents a key corporate milestone, positioning the company for enhanced shareholder liquidity and public market visibility ahead of its anticipated FDA 510(k) clearance.

"This is a significant step in our transparency journey," said Diallo M. Watts, Sr., Founder and CEO. "Filing Form 211 reflects our commitment to operating with the highest standards of corporate governance as we build toward commercialization, pending FDA 510(k) clearance."

The OTC filing does not constitute a public offering. All existing Regulation D and accredited investor requirements remain in effect.

Key Takeaway: The Form 211 filing signals RxAir360's readiness for a more visible market presence, reinforcing the company's commitment to investor transparency and long-term governance standards.